S
Susan A. Charman
Researcher at Monash University
Publications - 215
Citations - 13133
Susan A. Charman is an academic researcher from Monash University. The author has contributed to research in topics: Plasmodium falciparum & In vivo. The author has an hindex of 54, co-authored 208 publications receiving 11446 citations. Previous affiliations of Susan A. Charman include Florey Institute of Neuroscience and Mental Health & Rensselaer Polytechnic Institute.
Papers
More filters
Journal ArticleDOI
Strategies to Address Low Drug Solubility in Discovery and Development
Hywel David Williams,Natalie L. Trevaskis,Susan A. Charman,Ravi Mysore Shanker,William N. Charman,Colin W. Pouton,Christopher J.H. Porter +6 more
TL;DR: The article provides an integrated and contemporary discussion of current approaches to solubility and dissolution enhancement but has been deliberately structured as a series of stand-alone sections to allow also directed access to a specific technology where required.
Journal ArticleDOI
Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ
Paul A. Adlard,Robert A. Cherny,Robert A. Cherny,David Finkelstein,David Finkelstein,Elisabeth Gautier,Elysia Robb,Mikhalina Cortes,Irene Volitakis,Xiang Liu,Jeffrey P. Smith,Keyla Perez,Keyla Perez,Katrina M. Laughton,Katrina M. Laughton,Qiao-Xin Li,Qiao-Xin Li,Susan A. Charman,Joseph A. Nicolazzo,Simon Wilkins,Simon Wilkins,Karolina Deleva,Toni Lynch,Gaik Beng Kok,Craig W. Ritchie,Rudolph E. Tanzi,Roberto Cappai,Roberto Cappai,Colin L. Masters,Colin L. Masters,Kevin J. Barnham,Kevin J. Barnham,Ashley I. Bush,Ashley I. Bush +33 more
TL;DR: The current data demonstrate that ionophore activity, inhibition of in vitro metal-mediated Abeta reactions, and blood-brain barrier permeability are indices that predict a potential disease-modifying drug for AD.
Journal ArticleDOI
Identification of an antimalarial synthetic trioxolane drug development candidate.
Jonathan L. Vennerstrom,Sarah Arbe-Barnes,Reto Brun,Susan A. Charman,Francis C. K. Chiu,Jacques Chollet,Yuxiang Dong,Arnulf Dorn,Daniel Hunziker,Hugues Matile,Kylie Anne McIntosh,Maniyan Padmanilayam,Josefina Santo Tomas,Christian Scheurer,Bernard Scorneaux,Yuanqing Tang,Heinrich Urwyler,Sergio Wittlin,William N. Charman +18 more
TL;DR: Here it is described how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.
Journal ArticleDOI
Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound.
Susan A. Charman,William N. Charman,Mark Rogge,Terry D. Wilson,Frank J. Dutko,Colin W. Pouton +5 more
TL;DR: Self-emulsifying drug delivery systems (SEDDSs) represent a possible alternative to traditional oral formulations of lipophilic compounds and improved the reproducibility of the plasma profile in terms of the maximum plasma concentration (Cmax) and the time to reach the maximum concentration (tmax).
Journal ArticleDOI
A novel multiple-stage antimalarial agent that inhibits protein synthesis
Beatriz Baragaña,Irene Hallyburton,Marcus C. S. Lee,Marcus C. S. Lee,Neil R. Norcross,Raffaella Grimaldi,Thomas D. Otto,William R. Proto,Andrew M. Blagborough,Stephan Meister,Grennady Wirjanata,Andrea Ruecker,Leanna M. Upton,Tara S. Abraham,Mariana Justino de Almeida,Anupam Pradhan,Achim Porzelle,María Santos Martínez,Judith M. Bolscher,Andrew Woodland,Suzanne Norval,Fabio Zuccotto,John Thomas,Frederick R. C. Simeons,Laste Stojanovski,Maria Osuna-Cabello,Patrick M. Brock,Thomas S. Churcher,Katarzyna A. Sala,Sara E. Zakutansky,María Belén Jiménez-Díaz,Laura M. Sanz,Jennifer Riley,Rajshekhar Basak,Michael Campbell,Vicky M. Avery,Robert W. Sauerwein,Koen J. Dechering,Rintis Noviyanti,Brice Campo,Julie A. Frearson,Iñigo Angulo-Barturen,Santiago Ferrer-Bazaga,Francisco-Javier Gamo,Paul G. Wyatt,Didier Leroy,Peter Siegl,Michael J. Delves,Dennis E. Kyle,Sergio Wittlin,Jutta Marfurt,Ric N. Price,Robert E. Sinden,Elizabeth A. Winzeler,Susan A. Charman,Lidiya Bebrevska,David W. Gray,Simon Campbell,Alan H. Fairlamb,Paul Willis,Julian C. Rayner,David A. Fidock,Kevin D. Read,Ian H. Gilbert +63 more
TL;DR: DDD107498 was developed from a screening programme against blood-stage malaria parasites and its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis.